Add to ORKGPalivizumab efficiently blocks respiratory syncytial virus (RSV) infection in vitro. However, virus neutralization assays generally omit Fc region-mediated effects. We investigated the neutralization activity of RSV-specific monoclonal antibodies on cells with Fc receptors. Subneutralizing concentrations of antibodies resulted in antibody-dependent enhancement of RSV infection in monocytic cells. Contrary to antibodies targeting other epitopes, the neutralization by palivizumab was augmented in cells with Fc receptors. This unrecognized characteristic of palivizumab may be relevant for its performance in vivo
AbstractRespiratory syncytial virus (RSV) belongs to the family Paramyxoviridae and is the single mo...
Therapeutic options to control respiratory syncytial virus (RSV) are limited, thus development of ne...
Introduction Respiratory syncytial virus (RSV) is the single most important cause of severe respirat...
Palivizumab efficiently blocks respiratory syncytial virus (RSV) infection in vitro. However, virus ...
AbstractPalivizumab efficiently blocks respiratory syncytial virus (RSV) infection in vitro. However...
Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract infections and ...
Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract infections and ...
Respiratory Syncytial Virus (RSV) is one of the most important viral pathogen related to acute lower...
Respiratory syncytial virus (RSV) infection is a leading cause of hospitalization and mortality in y...
AbstractThe role of binding kinetics in determining neutralizing potency for antiviral antibodies is...
The respiratory syncytial virus (RSV) causes significant respiratory disease in young infants and th...
The neutralizing and enhancing activities of respiratory syncytial virus (RSV)-specific antibodies w...
Infants are protected from a severe respiratory syncytial virus (RSV) infection in the first months ...
Background. Palivizumab is a US Food and Drug Administration–approved monoclonal antibody for the pr...
Respiratory syncytial virus (RSV) causes substantial morbidity and mortality in young children and t...
AbstractRespiratory syncytial virus (RSV) belongs to the family Paramyxoviridae and is the single mo...
Therapeutic options to control respiratory syncytial virus (RSV) are limited, thus development of ne...
Introduction Respiratory syncytial virus (RSV) is the single most important cause of severe respirat...
Palivizumab efficiently blocks respiratory syncytial virus (RSV) infection in vitro. However, virus ...
AbstractPalivizumab efficiently blocks respiratory syncytial virus (RSV) infection in vitro. However...
Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract infections and ...
Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract infections and ...
Respiratory Syncytial Virus (RSV) is one of the most important viral pathogen related to acute lower...
Respiratory syncytial virus (RSV) infection is a leading cause of hospitalization and mortality in y...
AbstractThe role of binding kinetics in determining neutralizing potency for antiviral antibodies is...
The respiratory syncytial virus (RSV) causes significant respiratory disease in young infants and th...
The neutralizing and enhancing activities of respiratory syncytial virus (RSV)-specific antibodies w...
Infants are protected from a severe respiratory syncytial virus (RSV) infection in the first months ...
Background. Palivizumab is a US Food and Drug Administration–approved monoclonal antibody for the pr...
Respiratory syncytial virus (RSV) causes substantial morbidity and mortality in young children and t...
AbstractRespiratory syncytial virus (RSV) belongs to the family Paramyxoviridae and is the single mo...
Therapeutic options to control respiratory syncytial virus (RSV) are limited, thus development of ne...
Introduction Respiratory syncytial virus (RSV) is the single most important cause of severe respirat...